Navigation Links
TaiGen Biotechnology Announces Burixafor Collaboration with Cellex and the University Hospital Carl Gustav Carus Dresden in Germany

TAIPEI, March 18, 2015 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced the signing of an agreement to collaborate with Cellex GmbH and the University Hospital Carl Gustav Carus Dresden in Germany in an investigator-initiated clinical trial using burixafor in stem cell mobilization in healthy donors. The study titled "Burixafor in allogeneic poor mobilizers" is a Phase 2 open-label study to determine the effect of a single dose of burixafor in up to 37 poor mobilizers. The rate of donation success will be measured as the primary endpoint. Under the terms of the agreement, Cellex will be responsible for obtaining clinical trial approval and conduct of the trial and assume all associated costs. TaiGen will have the option to obtain and use the data for future development and filing of market authorization.

Professor Gerhard Ehninger, founder of Cellex and Chair of the Department of Hematology at the University Hospital commented, "We learned of burixafor at the 2013 American Society of Hematology meeting and were impressed with its efficacy in autologous transplantation. Currently approximately 5% of allogeneic donors fail to mobilize enough CD34+ cells to reach an optimal dose for transplantation using G-CSF. Patients receiving transplants with suboptimal CD34+ doses are at risk for delayed or incomplete engraftment and increased rate of infections. The stem cell mobilization activity of burixafor will be highly desirable in increasing CD34+ cell yields in poor mobilizing donors."

Dr. Ming-Chu Hsu, Chairman and CEO of TaiGen said, "We are delighted to work with Professor Ehninger, an experienced hematologist and key opinion leader. From our clinical study to date, we know that burixafor has excellent activity and safety in healthy volunteers and cancer patients. With Cellex as our partner we have access to a larger donor population and study its effect on donors who failed G-CSF. This collaboration with Professor Ehninger and Cellex enabled TaiGen to explore additional indications and increase the market potential of TG-0054."

About Cellex GmbH
Cellex, founded by Professor Ehninger in 2001, is the largest stem cell collection center in Germany and one of the largest in Europe. The two sites of Cellex in Dresden and Cologne together performed over 3,000 stem cell collections in 2014 and are serving donors and patients worldwide. 

About Burixafor
Burixafor, also known as TG-0054, is a novel, potent and selective chemokine receptor antagonist discovered by TaiGen. Burixafor rapidly mobilizes stem cells and progenitor cells from the bone marrow into peripheral circulation. Burixafor is currently in Phase 2 study in autologous stem cell transplantation in the US. Another Phase 2 study in chemosensitization is planned for China in 2015. Other potential indications also include regenerative medicine and ischemic diseases.

About TaiGen Biotechnology
TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In addition to TG-0054, TaiGen has two other NCEs in product portfolio: Nemonoxacin (oral formulation) has received NDA approval from Taiwan FDA and pending approval from China FDA; and TG-2349 is a pan-genotypic NS3/4A protease inhibitor currently in Phase 2.

For more information please contact:
Peter W. Tsao, PhD, Vice President of Business Development
Tel: +886-2-8177-7072

SOURCE Taigen Biotechnology
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan
2. First Gathering of Biotech Experts Aims to Establish Ethical Standards in Cellular Biotechnology at BEINGS 2015
3. Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc.
4. Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
5. TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China
6. Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index
7. TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan
8. Neurocrine Biosciences to Present at the Nomura Biotechnology Conference
9. Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU
10. The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene
11. The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
Post Your Comments:
(Date:11/19/2019)... ... November 19, 2019 , ... Liquid nutrients have reigned supreme ... space have been transitioning to powdered nutrients because of the cost-effectiveness and ease of ... difficulty in combining essential macro and micronutrients, most nutrient companies package them separately, forcing ...
(Date:11/19/2019)... ... 18, 2019 , ... San Antonio-based businesses, Rodkeys and Massage ... sales through a new partnership announced today. This collaboration has the potential to ... A selection of Rodkeys branded non-THC CBD products are now available at more ...
(Date:11/19/2019)... ... 2019 , ... Respected Hollywood actor and film director, Laurence ... Laurence Fishburne. The program’s central focus is to inform the general public about ... be aired on the show, a new segment covering TMJD (Temporomandibular Disorder) and ...
Breaking Medicine Technology:
(Date:11/16/2019)... ... 15, 2019 , ... As demand for legal medical marijuana ... well-managed dispensaries becomes more and more important, both for consumers and as part ... online, custom cannabis business plans is now increasing its support for marijuana dispensary ...
(Date:11/15/2019)... MIAMI (PRWEB) , ... November 15, 2019 , ... ... Anxiety and Depression Association of America (ADAA) puts the current figures ... any form of treatment. Such mental health issues manifest in many different ways, ...
(Date:11/15/2019)... (PRWEB) , ... November 15, 2019 , ... ... and co-builds next-generation cybersecurity and data science companies with nation-state experienced technical teams ... of its second-annual DataTribe Challenge is Code Dx Inc ., based in ...
(Date:11/14/2019)... ... ... Inland Detox, Inc. is proud of and grateful for its Chef, Arturo Banuelos, ... Mexico. The Chefs Latinos Guanajuato Festival Gastronomico was held at La Hacienda San Cristobal ... November 9, 2019. The event featured a total of 18 renowned Chef’s from Latin ...
(Date:11/14/2019)... ... 14, 2019 , ... In a first of its kind ... have performed a pioneering coronary intervention with an Impella heart assist device ... The new procedure offers surgeons another option to help save the lives of ...
Breaking Medicine News(10 mins):